¨ Form
10-K
|
¨ Form
11-K
|
¨ Form
20-F
|
x Form
10-Q
|
o Transition Report
on Form 10-K
|
o Transition Report
on Form 10-Q
|
o Transition Report
on Form 20-F
|
o Transition Report
on Form N-SAR
|
Full
name of registrant
|
Novelos
Therapeutics, Inc.
|
Former
name if applicable
|
|
Address
of principal executive office
|
One
Gateway Center, Suite 504
|
City,
state and zip code
|
Newton,
Massachusetts 02458
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before
the 15
th calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
Harry
S. Palmin
|
(617)
244-1616
|
(Name)
|
(Telephone
Number)
|
Date:
November 16, 2010
|
By:
|
/s/
Harry S. Palmin
|
|
Harry
S. Palmin
|
|||
President
and Chief Executive Officer
|
|||